Condition: Neuroblastoma · Sponsor: Giselle Sholler
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.
This description comes directly from the study's public registry record.
BCC Enroll · 7175310003 · BCCEnroll@pennstatehealth.psu.edu
Always discuss trial participation with your own doctor first.
| University of Alabama/Children's of Alabama | Birmingham, Alabama, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| UCSF Benioff Children's Hospital Oakland | Oakland, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| Connecticut Children's Hospital | Hartford, Connecticut, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| Arnold Palmer Hospital for Children | Orlando, Florida, United States | Recruiting |
| Augusta University Health | Augusta, Georgia, United States | Recruiting |
| Kapiolani Medical Center for Women and Children | Honolulu, Hawaii, United States | Recruiting |
| Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine | Louisville, Kentucky, United States | Recruiting |
| Children's Hospital and Clinics of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05489887